Posted by Michael Wonder on 14 Dec 2021
SMC approves first immunotherapy combination for advanced bowel cancer patients with rare mutation
14 December 2021 - Nivolumab plus ipilmumab has been accepted as a treatment option for adult patients by NHS Scotland for patients who have previously failed fluoropyrimidine-based chemotherapy.
BMS announced the Scottish Medicines Consortium has accepted nivolumab plus ipilmumab as a treatment option for adults with mismatch repair deficient or microsatellite instability-high advanced colorectal cancer.
The decision marks the first immunotherapy combination approved in Scotland for this patient group, who have a form of advanced bowel cancer.
